Bowman & Co S.C. Makes New $749,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Bowman & Co S.C. acquired a new stake in DexCom, Inc. (NASDAQ:DXCMFree Report) during the 1st quarter, Holdings Channel reports. The institutional investor acquired 5,397 shares of the medical device company’s stock, valued at approximately $749,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. DSM Capital Partners LLC acquired a new stake in DexCom in the 4th quarter valued at $28,000. Valley National Advisers Inc. raised its holdings in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the period. Riverview Trust Co acquired a new position in DexCom during the 1st quarter worth approximately $32,000. MV Capital Management Inc. boosted its holdings in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares during the period. Finally, Smithfield Trust Co grew its position in DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 165 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Up 2.9 %

Shares of NASDAQ:DXCM opened at $113.51 on Thursday. The company’s fifty day moving average is $124.29 and its two-hundred day moving average is $125.85. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The stock has a market capitalization of $45.14 billion, a price-to-earnings ratio of 73.23, a price-to-earnings-growth ratio of 2.69 and a beta of 1.22.

DexCom (NASDAQ:DXCMGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. Equities analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Transactions at DexCom

In related news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 49,633 shares of the business’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the transaction, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at $39,262,401.90. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,076 shares of company stock worth $7,544,030. 0.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on DXCM shares. Raymond James boosted their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Canaccord Genuity Group upped their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Redburn Atlantic began coverage on DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Citigroup boosted their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada started coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $140.33.

Read Our Latest Report on DXCM

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Recommended Stories

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.